Abingworth insists all options are still open for Amarin
This article was originally published in Scrip
Executive Summary
Amarin's largest shareholder has restated its commitment to the company following a UK newspaper report that it is seeking a buyer. Abingworth, which has seen its stake reduce from around 17% to about 10% since a public sale of American Depositary Shares in January which raised about $99 million, is "thrilled" with last week's better than expected Phase III results for the hypolipaemic AMR101 (scripintelligence.com, 18 April 2011), and took the view that "all avenues are open to the company", Dr Joseph Anderson, Abingworth partner and non-executive director of Amarin, told Scrip.